Castle Biosciences FY2022 revenue $137M (+46% YoY); guides FY2023 revenue $170-180M

CASTLE BIOSCIENCES INC

2022-FY EPS reported -$2.58 revenue$137,039,000

Full-year 2022 revenue $137.0M, up 46% from $94.1M; test reports 44,419, up 58%.
Q4 2022 revenue $38.3M (+53% YoY); test reports 12,644 (+53%).
Net loss $67.1M (incl. $36.3M stock compensation) vs $31.3M loss in 2021.
Adjusted EBITDA -$42.6M vs -$14.9M; cash and investments $258.6M at year-end.
FY2023 revenue outlook $170-180M; reaffirms 2025 targets of $255-330M revenue and cash flow positivity.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CASTLE BIOSCIENCES INC reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 28, 2023, Castle Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001447362-23-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.